Moderna

Moderna Headquarters Location

Cambridge

Moderna Photos

  • Ribbon cutting at 320 Bent St.
  • Moderna Therapeutics
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top employer by Science for the fifth year in a row. To learn more, visit www.modernatx.com.
Focused on Corporate Social Responsibility
Moderna's CSR efforts are focused on the development of mRNA medicines - including potential medicines for public health needs - as well as on our employees, the environment, our communities and strong corporate governance.
What is mRNA Science?
Messenger RNA, or mRNA, plays a fundamental role in human biology, transferring the instructions stored in DNA to make the proteins required in every living cell. Our approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease.
Delivering on the promise of mRNA therapies for rare diseases
Dr. Stephen Hoge, President, and Paolo Martini, Ph.D., CSO Rare Diseases, discuss newly published preclinical data supporting Moderna’s first rare liver disease development program, an mRNA therapeutic for methylmalonic acidemia (MMA).

Number of Employees in Moderna

501 à 1 000

Moderna Revenue

20 à 85 M (EUR)